Jennifer L. Cina

Learn More
STUDY OBJECTIVE To evaluate the safety and efficacy of valganciclovir 450 mg/day for 6 months for cytomegalovirus (CMV) prophylaxis in renal transplant recipients. DESIGN Single-center,(More)
  • 1